Checkpoint-primed allo-HCT in HL: cure gains, risk remains

Paul J Bröckelmann¹, Bastian von Tresckow^{1

2}

Affiliations

Editorial

Paul J Bröckelmann et al. Blood. 2025.

. 2025 Aug 21;146(8):911-912.

doi: 10.1182/blood.2025029908.

Paul J Bröckelmann¹, Bastian von Tresckow^{1

2}

No abstract available

Comment on

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis.
Perales MA, Awan FT, Boumendil A, Patel J, Castagna L, Angelucci E, Finel H, Kulagin A, Glass B, Corradini P, Herrera AF, Blaise D, Kharfan-Dabaja MA, Halahleh K, Ahmed S, Martínez C, Giebel S, Montoto S, Jones RJ, Ahmed N, Lynch RC, De Lima MJ, Shadman M, Sauter CS, Ahn KW, Hamadani M, Bazarbachi A, Sureda A. Perales MA, et al. Blood. 2025 Aug 21;146(8):1011-1029. doi: 10.1182/blood.2024027197. Blood. 2025. PMID: 40623049